JPMorgan analyst Chris Schott says EliLilly’s (LLY) Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidance ...
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for ...